LitCovid-sentences  

PMC:7195088 / 65752-69458 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T466 0-63 Sentence denotes Question 7. what is the optimal timing of treatment initiation?
T467 64-264 Sentence denotes Most clinical data on the timing of antiviral therapy initiation are derived from studies on viruses other than SARS-CoV-2, and it remains unclear whether these data can be extrapolated to SARS-CoV-2.
T468 265-448 Sentence denotes Previous studies in SARS-CoV-1 and influenza showed a possible favourable impact on mortality of early initiation of antiviral treatment after symptoms onset [[79], [80], [81], [82]].
T469 449-852 Sentence denotes With regard to SARS-CoV-2, although the results of the previously cited RCT comparing LPV/RTV versus standard of care eventually does not support the use of LPV/RTV in patients with COVID-19, it is also of note that the median time between symptom onset and randomization was 13 days (interquartile range, 11–16 days), so in most cases, the drug was initiated late during the course of the disease [22].
T470 853-981 Sentence denotes Consequently, we cannot exclude the possibility that an earlier initiation of LPV/RTV may be associated with improved prognosis.
T471 982-1201 Sentence denotes In this regard, we think the results of this RCT may be hypothesis generating and may help guide the design of further RCT evaluating the efficacy of LPV/RTV (and/or other antivirals) in an earlier phase of the disease.
T472 1202-1449 Sentence denotes However, until such RCT will be available, we think the currently available clinical evidence is insufficient to support the use of LPV/RTV and/or other antivirals for treating COVID-19 outside the framework of RCT or compassionate-use programmes.
T473 1450-1554 Sentence denotes The optimal time of chloroquine/hydroxychloroquine and corticosteroids initiation still remains unknown.
T474 1555-2051 Sentence denotes Although based on low-level evidence, the positive effect of virus clearance observed by Gautret et al. [41] was observed in a mixed group of non-ICU patients with upper respiratory tract symptoms, non-ICU patients with lower respiratory tract symptoms and asymptomatic subjects, which overall may support a positive effect of early hydroxychloroquine initiation in non-ICU settings (although information on the exact time of treatment initiation with respect to symptoms onset was not provided).
T475 2052-2199 Sentence denotes With regard to steroid treatment, there is currently no evidence of a positive impact of early initiation in non–critically ill, non-ARDS patients.
T476 2200-2458 Sentence denotes Although lack of evidence is not a synonym of lack of effect, in our opinion, steroid treatment, considering also its potential detrimental effects, should currently be limited to ARDS patients or non-ARDS patients with worsening conditions (see question 5).
T477 2460-2480 Sentence denotes Question 7 statement
T478 2481-2777 Sentence denotes Supportive therapy (symptomatic therapy, rehydration and oxygen supplementation, if necessary) should be provided as soon as the patient presents with respiratory or systemic symptoms including severe asthenia, high fever, persistent cough and/or clinical or radiologic signs of lung involvement.
T479 2778-3049 Sentence denotes Pending further evidence, in our opinion, antiviral treatments should not be initiated in patients with SARS-CoV-2 infection outside RCT or compassionate-use programmes (with the exception of early oseltamivir initiation in patients with suspected concomitant influenza).
T480 3050-3322 Sentence denotes Corticosteroids should be initiated early in well-defined categories of patients (patients with ARDS or with worsening of non-ARDS respiratory failure in the absence of bacterial/fungal superinfections), while their role in other COVID-19 patients still remains uncertain.
T481 3323-3706 Sentence denotes Although based on low-level evidence and pending RCT results, in our opinion, early hydroxychloroquine administration may be considered in COVID-19 patients who have moderate to severe symptoms, whereas further data are needed to better delineate the true balance between possible favourable effects and toxicity of hydroxychloroquine in mildly symptomatic and asymptomatic patients.